|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Telmisartan#Drug Interactions]] |
| {{Telmisartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| '''Aliskiren''': Do not co-administer [[aliskiren]] with MICARDIS in patients with diabetes. Avoid use of [[aliskiren]] with MICARDIS in patients with [[renal impairment]] (GFR <60 mL/min).
| |
| | |
| '''Digoxin''': When MICARDIS was co-administered with [[digoxin]], median increases in [[digoxin]] peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor [[digoxin]] levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the [[digoxin]] level within the therapeutic range.
| |
| | |
| '''Lithium''': Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including MICARDIS. Therefore, monitor serum [[lithium]] levels during concomitant use.
| |
| | |
| '''Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)''': In patients who are elderly, volume-depleted (including those on [[diuretic]] therapy), or with compromised renal function, co-administration of [[NSAIDs]], including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible [[acute renal failure]]. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and [[NSAID]] therapy.
| |
| | |
| The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by [[NSAIDs]] including selective COX-2 inhibitors.
| |
| | |
| Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and [[ramipril]] 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of [[ramipril]] 2.3- and 2.1-fold, respectively, and Cmax and AUC of [[ramipril]]at 2.4- and 1.5-fold, respectively. In contrast, Cmaxand AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and [[ramipril]], the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to [[ramipril]] and [[ramipril]]at in the presence of telmisartan. Concomitant use of MICARDIS and [[ramipril]] is not recommended.
| |
| | |
| Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with [[acetaminophen]], [[amlodipine]], [[glyburide]], [[simvastatin]], [[hydrochlorothiazide]], [[warfarin]], or [[ibuprofen]]. Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MICARDIS (TELMISARTAN) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfb9309f-e0df-4a55-9542-0e869fce05fb | publisher = | date = | accessdate = 24 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Benzoic acids]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:PPAR agonists]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |